These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3962 related articles for article (PubMed ID: 31054549)
1. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors]. Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549 [No Abstract] [Full Text] [Related]
2. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report]. Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308 [No Abstract] [Full Text] [Related]
3. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer]. Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307 [No Abstract] [Full Text] [Related]
4. Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: A phase 2 trial. Wang X; Yu Y; Meng W; Jiang D; Deng X; Wu B; Zhuang H; Wang C; Shen Y; Yang L; Zhu H; Cheng K; Zhao Y; Li Z; Qiu M; Gou H; Bi F; Xu F; Zhong R; Bai S; Wang Z; Zhou Z Radiother Oncol; 2018 Nov; 129(2):300-305. PubMed ID: 30381141 [TBL] [Abstract][Full Text] [Related]
5. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors]. Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301 [No Abstract] [Full Text] [Related]
6. [Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH)]. Wang YQ; Shen LJ; Wan JF; Zhang H; Wang Y; Wu X; Wang JW; Wang RJ; Sun YQ; Tong T; Huang D; Wang L; Sheng WQ; Zhang X; Cai GX; Xu Y; Cai SJ; Zhang Z; Xia F Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):448-458. PubMed ID: 37217353 [No Abstract] [Full Text] [Related]
7. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP; Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740 [TBL] [Abstract][Full Text] [Related]
8. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy]. Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306 [No Abstract] [Full Text] [Related]
9. [Application of short-course radiotherapy with total neoadjuvant therapy in the treatment of middle and low rectal cancer]. Chen CJ; Yang CK; Jian JL; Guan S; Xie MM Zhonghua Yi Xue Za Zhi; 2023 Jan; 103(4):271-277. PubMed ID: 36660788 [No Abstract] [Full Text] [Related]
10. Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer. Alvarez JA; Shi Q; Dasari A; Garcia-Aguilar J; Sanoff H; George TJ; Hong T; Yothers G; Philip P; Nelson G; Al Baghdadi T; Alese OB; Zambare W; Omer D; Verheij FS; Bercz A; Kim MJ; Buckley J; Williams H; George M; Garcia R; Gallagher P; O'Reilly EM; Meyerhardt JA; Crawley J; Shergill A; Horvat N; Romesser PB; Hall W; Smith JJ BMC Cancer; 2024 Jul; 24(1):901. PubMed ID: 39060961 [TBL] [Abstract][Full Text] [Related]
11. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial. Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study. Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042 [TBL] [Abstract][Full Text] [Related]
13. Clinical Analysis of the Efficacy and Safety of Different Neoadjuvant Strategies in the Treatment of Locally Advanced Rectal Cancer. Chen W; Wang W; Huang S; Zhou L; Wang G; Chen W Cancer Invest; 2024 Aug; 42(7):661-670. PubMed ID: 39037150 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study. Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J; Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845 [TBL] [Abstract][Full Text] [Related]
15. Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma. Jia AY; Narang A; Safar B; Zaheer A; Murphy A; Azad NS; Gearhart S; Fang S; Efron J; Warczynski T; Hacker-Prietz A; Meyer J Radiat Oncol; 2019 Aug; 14(1):147. PubMed ID: 31426827 [TBL] [Abstract][Full Text] [Related]
17. Total neoadjuvant treatment of locally advanced rectal cancer with high risk factors in Slovenia. Tuta M; Boc N; Brecelj E; Omejc M; Anderluh F; Ermenc AS; Peressutti AJ; Oblak I; Krebs B; Velenik V Radiol Oncol; 2019 Oct; 53(4):465-472. PubMed ID: 31652124 [TBL] [Abstract][Full Text] [Related]
18. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer]. Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial. Zhang W; Zhou H; Jiang J; Zhu Y; Zou S; Jiang L; Tang Y; Liang J; Sun Y; Jiang Z; Qu W; Li Y; Zhou A BMC Cancer; 2023 Jun; 23(1):592. PubMed ID: 37370032 [TBL] [Abstract][Full Text] [Related]
20. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J; BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]